MENU
 JPMA
  • Directions
  • Japanese
  • About JPMA

    About JPMA: Top

    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • About Medicines

    About Medicines: Top

    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates

    Committee News Top

    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • Newsletter
  • Newsroom

    Newsroom Top

    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research
Close
 JPMA

Return to Top

  • Patients and the General Public (About Medicines)
    Patients and the General Public (About Medications) Top
    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates
    Committee News Top
    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • About JPMA
    About JPMA: Top
    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies & Activities Top
    • Business Policy, Business Plan, and Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Code of Conduct
    • JPMA Code of Practice
    • Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
    • Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations
    • Guidelines for the Preparation of Summaries of Product Characteristics for Prescription Drugs (Abbreviation: Preparation Guidelines)
    • Clinical Research
    • Basic Principles and Guidelines for Action on Biodiversity
    • Guidelines on Fair Competition at Meetings of the Japan Pharmaceutical Manufacturers Association
    • Agreements, Manuals, and Guidelines
  • Newsroom
    Newsroom Top
    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research  Opens in a new window
  • Social Media Policy
  • Website Terms of Use
  • Access
  • Japanese
  • Home
  • About JPMA
  • Vision, Policy Proposals
  • Back Number: Vision, Proposals
  • JPMA Industrial Vision 2025

JPMA Industrial Vision 2025

Looking ahead to the year 2025, we envision a future in which R&D-based companies "bring drug discovery innovations to people around the world" and provide direction for their realization.

  • On the Formulation of
  • This Part
  • Background and Objectives of Vision Formulation
  • JPMA Industrial Vision 2025
  • Vision 1 "Driving next-generation medicine through advanced drug discovery: Contributing to P4+1 medicine
  • Vision 2 "Delivering innovative medicines to 8 billion people worldwide
  • Appendix 1 "Mission and Contribution to Global Health
  • Vision 3 "Leading the Japanese economy as a high value-added industry
  • Appendix 2 "Approach to Corporate Scale and Restructuring
  • Vision 4 "Supporting the realization of a health-advanced nation - a society where people can live long and healthy lives without anxiety
  • Vision 5 "Become a trusted industry with high aspirations
  • Reference Future Projections for 2025
  • Overview
  • Leaflet
  • Reference Materials

Related Information

  • JPMA Industry Vision 2025 Supplement
  • May 20, 2021: Materials from the Chairman's Press Conference

Share this page

  • Post
  • Share

TOP

Site Search

  • Home
  • About JPMA
  • Vision, Policy Proposals
  • Back Number: Vision, Proposals
  • JPMA Industrial Vision 2025
  • JPMA PR and Communications Activities
  • Pharmaceutical Research Institute
  • List of Non-Financial Information Disclosures by Member Companies
  • STOP AMR
  • About the JPMA
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • Newsroom
  • Patients and the General Public (About Medicines)
  • Clinical Trial Information
  • Committee Updates
  • JapanesePage will open in a new window.
  •  x
  •  Facebook
  •  YouTube
  • Site Map
  • Website Terms of Use
  • Basic Policy on Information Security
  • Social Media Policy
  • Links
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers’
’ Association (JPMA). All rights reserved.

Notification

This website uses automatic translation.
The translated content may not always be fully consistent with the original Japanese content.